Drug Shortage Report for CAPRELSA
| Report ID | 182714 |
| Drug Identification Number | 02378582 |
| Brand name | CAPRELSA |
| Common or Proper name | CAPRELSA 100 mg |
| Company Name | SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | VANDETANIB |
| Strength(s) | 100MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 3 |
| ATC code | L01XE |
| ATC description | OTHER ANTINEOPLASTIC AGENTS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2023-02-06 |
| Actual start date | |
| Estimated end date | 2023-02-17 |
| Actual end date | 2023-02-07 |
| Shortage status | Resolved |
| Updated date | 2023-02-08 |
| Company comments | Supply delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Customer service contact info: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2023-02-08 | English | Compare |
| v5 | 2023-02-07 | French | Compare |
| v4 | 2023-02-07 | English | Compare |
| v3 | 2023-02-07 | English | Compare |
| v2 | 2023-01-30 | French | Compare |
| v1 | 2023-01-30 | English | Compare |
Showing 1 to 6 of 6